-
ABCL Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
AbCellera Biologics (ABCL)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 151.64 mm | 151.64 mm | 151.64 mm | 151.64 mm | 151.64 mm | 151.64 mm |
Cash burn (monthly) | 7.22 mm | 3.82 mm | 31.22 mm | 25.67 mm | 9.63 mm | 10.01 mm |
Cash used (since last report) | 30.85 mm | 16.29 mm | 133.31 mm | 109.62 mm | 41.11 mm | 42.76 mm |
Cash remaining | 120.79 mm | 135.35 mm | 18.33 mm | 42.02 mm | 110.53 mm | 108.88 mm |
Runway (months of cash) | 16.7 | 35.5 | 0.6 | 1.6 | 11.5 | 10.9 |
13F holders | Current |
---|---|
Total holders | 140 |
Opened positions | 19 |
Closed positions | 30 |
Increased positions | 51 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 267.52 bn |
Total shares | 177.97 mm |
Total puts | 193.80 k |
Total calls | 98.00 k |
Total put/call ratio | 2.0 |
Largest owners | Shares | Value |
---|---|---|
Carl L. G. Hansen | 55.80 mm | $0.00 |
Baker Bros. Advisors | 27.53 mm | $71.57 bn |
Baillie Gifford & Co | 12.89 mm | $33.53 bn |
Voya Investment Management | 10.62 mm | $27.62 bn |
Thiel Peter | 10.18 mm | $0.00 |
Prosight Management | 9.08 mm | $23.61 bn |
DCVC Bio | 7.31 mm | $0.00 |
Ubs Global Asset Management Americas | 4.59 mm | $11.93 bn |
Orbimed Advisors | 4.18 mm | $10.87 bn |
ArrowMark Colorado | 4.11 mm | $10.67 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jan 25 | Carl L. G. Hansen | Share option Common Shares | Grant | Acquire A | No | No | 2.93 | 2,730,109 | 8.00 mm | 10,990,332 |
1 Jan 25 | Andrew Booth | Share option Common Shares | Grant | Acquire A | No | No | 2.93 | 1,352,054 | 3.96 mm | 7,942,951 |
1 Jan 25 | Veronique Lecault | Share option Common Shares | Grant | Acquire A | No | No | 2.93 | 832,033 | 2.44 mm | 4,661,804 |
1 Jan 25 | Tryn Stimart | Share option Common Shares | Grant | Acquire A | No | No | 2.93 | 832,033 | 2.44 mm | 4,106,747 |
4 Dec 24 | Thermopylae | Common Shares | Gift | Dispose G | No | No | 0 | 286,000 | 0.00 | 55,800,009 |